Regeneron Pharmaceuticals $REGN and co-developer Sanofi $SNY announced that the FDA has agreed to review the Biologics License Application (BLA) seeking approval of dupilumab , meant to cure inadequately controlled moderate-to-severe atopic dermatitis (AD), a Breakthrough Therapy-tagged use. If the regulator approves the treatment, it would be the first systemic therapy for the condition. The FDA�s action date is March 29, 2017.